发布求助
文献互助 智能选刊 最新文献

Personalized medicine最新文献

筛选
英文 中文
Healthcare professionals' knowledge, attitudes and future expectations towards personalized medicine. 医疗保健专业人员对个性化医疗的知识、态度和未来期望。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-18 DOI: 10.2217/pme-2020-0185
Tayachew Admas, Aklilu Banjaw
{"title":"Healthcare professionals' knowledge, attitudes and future expectations towards personalized medicine.","authors":"Tayachew Admas,&nbsp;Aklilu Banjaw","doi":"10.2217/pme-2020-0185","DOIUrl":"https://doi.org/10.2217/pme-2020-0185","url":null,"abstract":"<p><p><b>Aim:</b> Personalized medicine (PM) is a novel approach to diagnose and treat disease. The study assessed the knowledge, attitudes and future expectations of healthcare professionals (HPs) towards PM in Ethiopia. <b>Materials & methods:</b> A cross-sectional survey with primary data and a simple random sampling technique was applied to collect data. <b>Results:</b> Our study revealed from a total of 384 respondents, 98 (25.5%), 146 (38%) and 140 (36.5%) had good, medium and poor knowledge of PM, respectively. However, 172 (44.8%), 185 (48.2%) and 27 (7%) had positive, neutral and negative attitudes towards PM, respectively. <b>Conclusion:</b> Most respondent's future expectations of PM were positive. Education level had a significant association with attitudes and other sociodemographic variables were not significant for both knowledge and attitude.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"483-490"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A GRIN3A polymorphism may be associated with glucocorticoid-induced symptomatic osteonecrosis in children with acute lymphoblastic leukemia. GRIN3A多态性可能与急性淋巴细胞白血病儿童糖皮质激素诱导的症状性骨坏死有关。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-18 DOI: 10.2217/pme-2020-0167
Nathalie K Zgheib, Habib El-Khoury, Dimitri Maamari, Maya Basbous, Raya Saab, Samar A Muwakkit
{"title":"A <i>GRIN3A</i> polymorphism may be associated with glucocorticoid-induced symptomatic osteonecrosis in children with acute lymphoblastic leukemia.","authors":"Nathalie K Zgheib,&nbsp;Habib El-Khoury,&nbsp;Dimitri Maamari,&nbsp;Maya Basbous,&nbsp;Raya Saab,&nbsp;Samar A Muwakkit","doi":"10.2217/pme-2020-0167","DOIUrl":"https://doi.org/10.2217/pme-2020-0167","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the association between candidate genetic polymorphisms and glucocorticoid-induced osteonecrosis in Arab children treated for acute lymphoblastic leukemia. <b>Methods:</b> A total of 189 children treated for acute lymphoblastic leukemia were genotyped for four SNPs with allele discrimination assays. The incidence and timing of radiologically confirmed symptomatic grade 4 osteonecrosis were classified based on the Ponte di Legno toxicity working group consensus definition. <b>Results:</b> Thirteen children developed grade 4 osteonecrosis (6.8%), of whom 12 received the intermediate/high-risk treatment protocol. <i>GRIN3A</i> variant allele carriers had to stop dexamethasone therapy earlier resulting in significantly shorter duration of dexamethasone treatment (mean [95% CI]: 75.17 [64.28-86.06] vs 85.90 [81.22-90.58] weeks; p = 0.054) and lower cumulative dose (mean [95% CI]: 1118.11 [954.94-1281.29] vs 1341.14 [1264.17-1418.11] mg/m<sup>2;</sup> p = 0.011). <b>Conclusion:</b> This is the first pharmacogenomics evaluation of the association between <i>GRIN3A</i> variants and glucocorticoid-induced osteonecrosis in Arab children.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"431-439"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
After decades, RAS mutation has finally become a therapeutic target. 几十年后，RAS突变终于成为治疗靶点。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-18 DOI: 10.2217/pme-2021-0015
Nabih Naim, Sara Moukheiber, Karim Jaber, Hampig Raphael Kourie
{"title":"After decades, RAS mutation has finally become a therapeutic target.","authors":"Nabih Naim,&nbsp;Sara Moukheiber,&nbsp;Karim Jaber,&nbsp;Hampig Raphael Kourie","doi":"10.2217/pme-2021-0015","DOIUrl":"https://doi.org/10.2217/pme-2021-0015","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"523-525"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39524337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations. SLCO1B1基因他汀类转运保护性单倍型在墨西哥人群中的患病率。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-22 DOI: 10.2217/pme-2020-0172
Alma Faviola Favela-Mendoza, Brenda Guadalupe Rodríguez-Rodríguez, Eduardo Rojas-Prado, Mariana Chávez-Arreguin, José Alonso Aguilar-Velázquez, Gabriela Martínez-Cortés, Héctor Rangel-Villalobos
{"title":"Prevalence of protective haplotypes of the <i>SLCO1B1</i> gene for statin transport in Mexican populations.","authors":"Alma Faviola Favela-Mendoza,&nbsp;Brenda Guadalupe Rodríguez-Rodríguez,&nbsp;Eduardo Rojas-Prado,&nbsp;Mariana Chávez-Arreguin,&nbsp;José Alonso Aguilar-Velázquez,&nbsp;Gabriela Martínez-Cortés,&nbsp;Héctor Rangel-Villalobos","doi":"10.2217/pme-2020-0172","DOIUrl":"https://doi.org/10.2217/pme-2020-0172","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the genetic distribution of the <i>rs4149056</i> and <i>rs2306283</i> variants in the <i>SLCO1B1</i> gene in Mexican Mestizo (admixed) and Native American groups. <b>Materials & methods:</b> We recruited 360 volunteers who were qPCR-genotyped with TaqMan probes. <b>Results:</b> Allele and genotype frequencies are reported. Among the expected <i>rs4149056</i>-<i>rs2306283</i> haplotypes, T-A (42.35-58.47%) was the most prevalent which relates to the normal activity of the OATP1B1 transporter. This was followed by the T-G haplotype associated with further statin transport and cholesterol reduction (32.49-43.76%). <b>Conclusion:</b> Based on these <i>SLCO1B1</i> gene variants, we confirmed that a minimum fraction of the Mexican study populations would be at risk from decreasing simvastatin transport and the development of statin-induced myopathy.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"533-540"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39540499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of serum miR-101-3p expression in patients with neonatal sepsis. 新生儿脓毒症患者血清miR-101-3p表达的临床意义
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-06 DOI: 10.2217/pme-2020-0182
Juan Zhang, Xinwei Xu, Min Wang
{"title":"Clinical significance of serum <i>miR-101-3p</i> expression in patients with neonatal sepsis.","authors":"Juan Zhang,&nbsp;Xinwei Xu,&nbsp;Min Wang","doi":"10.2217/pme-2020-0182","DOIUrl":"https://doi.org/10.2217/pme-2020-0182","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to evaluate the levels and functions of <i>miR-101-3p</i> in neonatal sepsis (NS). <b>Materials & methods:</b> Quantitative real-time PCR was conducted to investigate the expression of <i>miR-101-3p</i> and the receiver operating characteristic curve was applied to manifest its diagnostic effects. <b>Results:</b><i>miR-101-3p</i> was increased in the NS patients and the dysregulation of <i>miR-101-3p</i> was associated with levels of procalcitonin, CRP, IL-8 and TNF-α. The combination of <i>miR-101-3p</i> and procalcitonin could function as a promising indicator in distinguishing NS patients. The silenced <i>miR-101-3p</i> reversed the increased levels of TNF-α and IL-8 caused by lipopolysaccharide <i>in vitro</i>. <i>DUSP1</i> was identified as a direct target gene of <i>miR-101-3p</i> in NS. <b>Conclusion:</b> The abundance of <i>miR-101-3p</i> facilitated the inflammation in NS by targeting <i>DUSP1</i>.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"541-550"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39486847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Personalized therapy: can it tame the COVID-19 monster? 个性化疗法：它能驯服 COVID-19 怪兽吗？
IF 1.7 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-15 DOI: 10.2217/pme-2021-0077
Mohd Arish, Farha Naz
{"title":"Personalized therapy: can it tame the COVID-19 monster?","authors":"Mohd Arish, Farha Naz","doi":"10.2217/pme-2021-0077","DOIUrl":"10.2217/pme-2021-0077","url":null,"abstract":"<p><p>SARS-CoV-2, a recently emerged zoonotic virus, has resulted in unstoppable high morbidity and mortality rates worldwide. However, due to a limited knowledge of the dynamics of the SARS-CoV-2 infection, it has been observed that the current COVID-19 therapy has led to some clinical repercussions. We discuss the adverse effects of drugs for COVID-19 primarily based on some clinical trials. As therapeutic efficacy and toxicity of therapy may vary due to different, genetic determinants, sex, age and the ethnic background of test subjects, hence biomarker-based personalized therapy could be more appropriate. We will share our thoughts on the current landscape of personalized therapy as a roadmap to fight against SARS-CoV-2 or another emerging pathogen.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"583-593"},"PeriodicalIF":1.7,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39517746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of miR-101 in esophageal and gastric cancer. miR-101在食管癌和胃癌中的作用。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-17 DOI: 10.2217/pme-2021-0024
Athanasios Syllaios, Stratigoula Sakellariou, Nikolaos Garmpis, Eleni Sarlani, Christos Damaskos, Konstantinos Apostolou, Stylianos Kykalos, Maria Gazouli, Ioannis Karavokyros, Dimitrios Schizas
{"title":"The role of miR-101 in esophageal and gastric cancer.","authors":"Athanasios Syllaios,&nbsp;Stratigoula Sakellariou,&nbsp;Nikolaos Garmpis,&nbsp;Eleni Sarlani,&nbsp;Christos Damaskos,&nbsp;Konstantinos Apostolou,&nbsp;Stylianos Kykalos,&nbsp;Maria Gazouli,&nbsp;Ioannis Karavokyros,&nbsp;Dimitrios Schizas","doi":"10.2217/pme-2021-0024","DOIUrl":"https://doi.org/10.2217/pme-2021-0024","url":null,"abstract":"<p><p>miR-101 is downregulated in various types of cancer, leading to the notion that miR-101 acts as a suppressor in cancer cell progression. The comprehensive mechanisms underlying the effects of miR-101 and the exact role of miR-101 dysregulations in esophagogastric tumors have not been fully elucidated. This review aims to summarize all current knowledge on the association between miR-101 expression and esophagogastric malignancies and to clarify the pathogenetic pathways and the possible prognostic and therapeutic role of miR-101 in those cancer types. miR-101 seems to play crucial role in esophageal and gastric cancer biology and tumorigenesis. It could also be a promising novel diagnostic and therapeutic target, as well as it may serve as a significant predictive biomarker in esophagogastric cancer.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"491-499"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39318825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Association of NQO1Pro187Ser polymorphism with clinical outcomes and survival of lung cancer patients treated with platinum chemotherapy. NQO1Pro187Ser多态性与铂类化疗肺癌患者临床结局和生存期的关系
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-07-01 Epub Date: 2021-05-11 DOI: 10.2217/pme-2020-0119
Harleen Kaur Walia, Navneet Singh, Siddharth Sharma
{"title":"Association of <i>NQO1Pro187Ser</i> polymorphism with clinical outcomes and survival of lung cancer patients treated with platinum chemotherapy.","authors":"Harleen Kaur Walia,&nbsp;Navneet Singh,&nbsp;Siddharth Sharma","doi":"10.2217/pme-2020-0119","DOIUrl":"https://doi.org/10.2217/pme-2020-0119","url":null,"abstract":"<p><p><b>Background:</b> The study was carried out to evaluate the association of <i>NQO1 P187S</i> polymorphism in North Indian lung cancer (LC) patients. We determined the effect of this polymorphic variant on the survival of LC patients. <b>Patients & methods/results:</b> This case-control study comprised a total of 1100 subjects. The genotyping was carried out using PCR-RFLP and statistical analysis was carried out. The variant TT genotype exhibited 3.5-fold higher odds in subjects with stage III (p = 0.0006), fivefold higher odds of lymph-node invasion (p = 0.007) and an odd of <1 in case of metastasis (p = 0.0028). Patients possessing TT genotype and administered with paclitaxel, exhibited a poor survival (3.57 vs 12.20 months; hazard ratio = 7.95; p = 0.0098). <b>Conclusion:</b> These results suggest that <i>NQO1</i> variant genotype was not found to modulate risk toward LC. However, the variant genotype was found to be strongly correlated with stage III LC, lymph node invasion and was found to be positively correlating with metastasis.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 4","pages":"333-346"},"PeriodicalIF":2.3,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38968766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Developing new frameworks to value genomic information: accounting for complexity. 开发新的框架来评估基因组信息:计算复杂性。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-07-01 Epub Date: 2021-05-11 DOI: 10.2217/pme-2021-0023
Martin Eden
{"title":"Developing new frameworks to value genomic information: accounting for complexity.","authors":"Martin Eden","doi":"10.2217/pme-2021-0023","DOIUrl":"https://doi.org/10.2217/pme-2021-0023","url":null,"abstract":"Current frameworks & their limitations Decisions have to be made about how to allocate the finite resources available to healthcare systems. Frameworks exist that can aid decisions about whether a new healthcare intervention should be approved for use in a healthcare system. These frameworks are typically underpinned by a formal approach to economic evaluation called cost– effectiveness analysis (CEA) and are primarily driven by the tenet that population health should be maximized. In a CEA, two or more interventions are assessed in terms of their costs and outcomes to determine the relative cost–effectiveness of an intervention compared with its alternatives. To enable comparisons between different types of healthcare interventions in a CEA, it is preferable to use a standard, common outcome measure: the qualityadjusted life-year (QALY). Mortality effects and quality of life attributable to ‘health’ are captured by the QALY with ‘health’ being narrowly defined by the scope of recommended survey tools such as the EQ-5D [1]. Generally speaking, the frameworks have proved useful for resource allocation decision making and have been successfully adopted in a number of jurisdictions across the world. There are, however, specific situations in which QALY-based frameworks, as currently applied, are inadequate. Notably, limitations have been identified where genomic information forms part of a complex intervention, for example, in precision medicine initiatives [2,3]. Interventions which utilize genomic information are complex, in that multiple elements combine to produce multifaceted outcomes. Importantly, these outcomes can extend beyond the confines of ‘health’ as conceptualized in the QALY.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 4","pages":"329-332"},"PeriodicalIF":2.3,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/c2/pme-18-329.PMC8242980.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38900334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ethics and equity in rare disease research and healthcare. 罕见病研究和保健中的伦理与公平。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-07-01 Epub Date: 2021-06-04 DOI: 10.2217/pme-2020-0144
Maria Koromina, Vasileios Fanaras, Gareth Baynam, Christina Mitropoulou, George P Patrinos
{"title":"Ethics and equity in rare disease research and healthcare.","authors":"Maria Koromina,&nbsp;Vasileios Fanaras,&nbsp;Gareth Baynam,&nbsp;Christina Mitropoulou,&nbsp;George P Patrinos","doi":"10.2217/pme-2020-0144","DOIUrl":"https://doi.org/10.2217/pme-2020-0144","url":null,"abstract":"Rapid advances in next-generation sequencing technology, particularly whole exome sequencing and whole genome sequencing, have greatly affected our understanding of genetic variation underlying rare genetic diseases. Herein, we describe ethical principles of guiding consent and sharing of genomics research data. We also discuss ethical dilemmas in rare diseases research and patient recruitment policies and address bioethical and societal aspects influencing the ethical framework for genetic testing. Moreover, we focus on addressing ethical issues surrounding research in low- and middle-income countries. Overall, this perspective aims to address key aspects and issues for building proper ethical frameworks, when conducting research involving genomics data with a particular emphasis on rare diseases and genetics testing.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 4","pages":"407-416"},"PeriodicalIF":2.3,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38980372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信